DR. JEROME B ZELDIS, MD
Medical Practice at Library Pl, Princeton, NJ
License number
New Jersey MA65020
Category
Medical Practice
Type
Health Educator
License number
New Jersey 198021-1
Category
Medical Practice
Type
Health Educator
Address
Address
151 Library Pl, Princeton, NJ 08540
Phone
(732) 672-5958
(908) 673-9001 (Fax)
(908) 673-9001 (Fax)
Personal information
See more information about JEROME B ZELDIS at radaris.comName
Address
Phone
151 Library Pl, Princeton, NJ 08540
Princeton, NJ
151 Library Pl, Princeton, NJ 08540
157 Christopher Dr, Princeton, NJ 08540
Professional information
Methods For Treatment Of Ovarian, Colorectal Or Pancreatic Cancer Using 4-(Aminno)-2(2,6-Dioxo(3-Piperidyl)-Isoindoline-1,3-Dione
US Patent:
2007029, Dec 27, 2007
Filed:
Jul 27, 2007
Appl. No.:
11/881756
Inventors:
Jerome Zeldis - Princeton NJ, US
International Classification:
A61K 31/704, A61K 31/4353, A61K 31/445, A61K 31/7115, A61P 35/00, A61K 31/706, A61K 31/573
US Classification:
514033000, 514171000, 514280000, 514323000, 514049000, 514050000
Abstract:
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Methods For Treating Diffuse Large B-Cell Lymphoma With 3-(4-Amino-1-Oxo-1,3-Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione In Combination With Second Active Agents
US Patent:
2013030, Nov 14, 2013
Filed:
Jul 15, 2013
Appl. No.:
13/942232
Inventors:
Jerome B. Zeldis - Princeton NJ, US
International Classification:
A61K 31/454, A61K 45/06, A61K 39/395
US Classification:
4241331
Abstract:
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Dr. Jerome B Zeldis, Princeton NJ - MD (Doctor of Medicine)
Specialties:
Gastroenterology
Address:
151 Library Pl, Princeton 08540
(732) 672-5958 (Phone), (908) 673-9001 (Fax)
(732) 672-5958 (Phone), (908) 673-9001 (Fax)
Certifications:
Gastroenterology, 1983, Internal Medicine, 1981
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Yale University
Graduated: 1978
UCLA Ctr Hlth Scis
Massachusetts General Hospital
Yale University
Graduated: 1978
UCLA Ctr Hlth Scis
Massachusetts General Hospital
Methods And Compositions Using Immunomodulatory Compounds For The Treatment And Management Of Central Nervous System Disorders Or Diseases
US Patent:
2008022, Sep 18, 2008
Filed:
May 23, 2008
Appl. No.:
12/154575
Inventors:
Jerome B. Zeldis - Princeton NJ, US
Herbert Faleck - West Orange NJ, US
Peter H. Schafer - Somerset NJ, US
Herbert Faleck - West Orange NJ, US
Peter H. Schafer - Somerset NJ, US
International Classification:
A61K 31/445, A61P 25/16, A61P 29/00
US Classification:
514323
Abstract:
Methods of treating, preventing and/or managing central nervous system disorders, such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) and related syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound of the invention, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Methods For Treating Brain Cancer Using 3-(4-Amino-1-Oxo-1,3-Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione Or 4-(Amino)-2-(2,6 Dioxo(3-Piperidyl))-Isoindoline-1,3-Dione
US Patent:
2008021, Sep 11, 2008
Filed:
May 8, 2008
Appl. No.:
12/151760
Inventors:
Jerome B. Zeldis - Princeton NJ, US
International Classification:
A61K 31/454, A61P 35/00, A61K 38/21, A61K 38/20, A61K 31/4375, A61K 31/522, A61K 31/573, A61K 31/704, A61K 31/7068, A61K 31/675, A61K 31/4965
US Classification:
424 852, 514323, 424 854, 514 12, 514283, 51426336, 514180, 514 34, 514 49, 514171, 514110, 51425506
Abstract:
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Method For The Treatment Of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione
US Patent:
2009001, Jan 8, 2009
Filed:
May 5, 2004
Appl. No.:
11/579355
Inventors:
Jerome B. Zeldis - Princeton NJ, US
Assignee:
CELGENE CORPORATION - Warren NJ
International Classification:
A61K 38/21, A61K 31/4035, A61P 35/00
US Classification:
424 857, 514416
Abstract:
Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agent is capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of MPD. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Methods Using 3-(4-Amino-1-Oxo-1,3-Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione For Treatment Of Mantle Cell Lymphomas
US Patent:
2008003, Feb 14, 2008
Filed:
Aug 1, 2007
Appl. No.:
11/888881
Inventors:
Jerome Zeldis - Princeton NJ, US
International Classification:
A61K 31/496, A61K 39/395, A61P 35/00
US Classification:
424133100, 514339000
Abstract:
Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
Methods For Treatment Of Cognitive And Menopausal Disorders With D-Threo Methylphenidate
US Patent:
2006018, Aug 17, 2006
Filed:
Apr 11, 2006
Appl. No.:
11/402385
Inventors:
Jerome Zeldis - Princeton NJ, US
Andrew Zeitlin - Basking Ridge NJ, US
Herbert Faleck - West Orange NJ, US
Vikram Khetani - Short Hills NJ, US
Maghsoud Dariani - Fanwood NJ, US
David Sterling - Branchburg NJ, US
Andrew Zeitlin - Basking Ridge NJ, US
Herbert Faleck - West Orange NJ, US
Vikram Khetani - Short Hills NJ, US
Maghsoud Dariani - Fanwood NJ, US
David Sterling - Branchburg NJ, US
International Classification:
A61K 31/445
US Classification:
514317000
Abstract:
In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising -threo methylphenidate that is substantially free of -threo methylphenidate and of erythro forms of methylphenidate.
Chronic, Bolus Adminstration Of D-Threo Methylphenidate
US Patent:
2009008, Apr 2, 2009
Filed:
Dec 9, 2008
Appl. No.:
12/331127
Inventors:
Maghsoud M. Dariani - Fanwood NJ, US
Andrew L. Zeitlin - Millington NJ, US
Jerome B. Zeldis - Princeton NJ, US
Andrew L. Zeitlin - Millington NJ, US
Jerome B. Zeldis - Princeton NJ, US
Assignee:
Celgene Corporation - Warren NJ
International Classification:
A61K 31/4458, A61P 25/00
US Classification:
514317
Abstract:
Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.
Chronic, Bolus Administration Of D-Threo Methylphenidate
US Patent:
5922736, Jul 13, 1999
Filed:
Sep 29, 1997
Appl. No.:
8/937684
Inventors:
Maghsoud M. Dariani - Fanwood NJ
Andrew L. Zeitlin - Millington NJ
Jerome B. Zeldis - Princeton NJ
Andrew L. Zeitlin - Millington NJ
Jerome B. Zeldis - Princeton NJ
Assignee:
Celegene Corporation - Warren NJ
International Classification:
A61K 31445
US Classification:
514317
Abstract:
Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.